• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Analyst: Be wary of big pharma stocks

Analyst: Be wary of big pharma stocks

June 3, 2011
CenterWatch Staff

Investors should be wary of global pharmaceutical stocks over the next six months, a Jefferies & Co. analyst said, because the stocks have become overpriced even though the companies will face a tough future, according to an Associated Press report.

Analyst Jeffrey Holford said pharmaceutical stocks have rallied over the last two months because of solid first-quarter results and recent product approvals, along with uncertainty in other sectors of the market. But Holford thinks results from drug companies will remain weak at least through the third quarter of this year.

"The recent rally in the pharma sector... has prompted many generalists and commentators on the sector to speculate that the prolonged period of underperformance by the sector may finally be over," he said. However, Holford said, the next 12 to 18 months "will likely see the worst period of top-line growth and margin pressure ever seen by the industry" as patents on many popular products expire, allowing low-cost generic versions to reach the market.

The rollout of the U.S. healthcare overhaul will also continue, and state and federal budgets will remain tight.

Holford added that changes in R&D procedures have not really started to pay off, although there are encouraging signs.

He said Pfizer, Novo Nordisk, GlaxoSmithKline and Bayer are the companies most likely to top expectations in the months ahead. Holford is less optimistic about Sanofi, Bristol-Myers Squibb, Merck and Eli Lilly.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing